Sio Gene Therapies Inc. Common Stock
SIOX
SIOX was delisted on the 22nd of March, 2023.
48 hedge funds and large institutions have $27.6M invested in Sio Gene Therapies Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 13 reducing their positions, and 14 closing their positions.
63% more call options, than puts
Call options by funds: $205K | Put options by funds: $126K
15% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 13
14% less funds holding
Funds holding: 56 → 48 (-8)
31% less capital invested
Capital invested by funds: $39.9M → $27.6M (-$12.3M)
50% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$754K |
| 2 |
BlackRock
New York
|
+$689K |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$652K |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
+$548K |
| 5 |
CC
Clearline Capital
New York
|
+$388K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.07M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$935K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$453K |
| 4 |
Renaissance Technologies
New York
|
-$282K |
| 5 |
Two Sigma Investments
New York
|
-$253K |
SIOX Hedge Fund Activity: Q4 2021 in Review
48 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q4 2021, worth a combined $27.6M — down 31% from $39.9M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of SIOX and 7 opened new positions — a net loss of 7 holders — while 13 trimmed existing stakes and 15 added.
The largest buyer was Suvretta Capital Management, adding an estimated $754K. The largest seller was Opaleye Management, exiting entirely with an estimated $2.07M sold.
- 48 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q4 2021, down from 56 in Q3 2021.
- Funds reported $27.6M of Sio Gene Therapies Inc. Common Stock stock for Q4 2021, down 31% quarter-over-quarter.
- 7 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q4 2021 and 14 closed out, a net change of -7 holders.
- The largest Sio Gene Therapies Inc. Common Stock buyer in Q4 2021 was Suvretta Capital Management, an estimated $754K added.
- The largest Sio Gene Therapies Inc. Common Stock seller in Q4 2021 was Opaleye Management, an estimated $2.07M sold.
Based on aggregated 13F filings for Q4 2021.